{"id":70604,"date":"2026-07-24T21:08:57","date_gmt":"2026-07-24T13:08:57","guid":{"rendered":"https:\/\/flcube.com\/?p=70604"},"modified":"2026-07-24T21:08:58","modified_gmt":"2026-07-24T13:08:58","slug":"changchun-high-tech-subsidiary-genescience-files-sle-clinical-application-for-novel-dual-target-baff-april-inhibitor-gensci136","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=70604","title":{"rendered":"Changchun High-Tech Subsidiary GeneScience Files SLE Clinical Application for Novel Dual-Target BAFF\/APRIL Inhibitor GenSci136"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Changchun High-Tech Industries (Group) Co., Ltd.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/beta\/quote\/000661:SHE\">SHE: 000661<\/a>) announced today that its subsidiary <strong>GeneScience Pharmaceuticals<\/strong> has submitted a <strong>clinical trial application<\/strong> in China for <strong>GenSci136<\/strong>, a novel Class 1 therapeutic biological product targeting <strong>systemic lupus erythematosus (SLE)<\/strong>. The investigational agent features a <strong>dual-target mechanism<\/strong> simultaneously blocking both <strong>BAFF<\/strong> (B-cell activating factor) and <strong>APRIL<\/strong> (a proliferation-inducing ligand) signaling pathways, representing a next-generation approach to modulating humoral immunity in autoimmune diseases.<\/p>\n\n\n\n<h2 id=\"h-development-milestone\" class=\"wp-block-heading\">Development Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Parent Company<\/strong><\/td><td>Changchun High-Tech (SHE: 000661)<\/td><\/tr><tr><td><strong>Subsidiary<\/strong><\/td><td>GeneScience Pharmaceuticals<\/td><\/tr><tr><td><strong>Product<\/strong><\/td><td>GenSci136 (Class 1 therapeutic biological)<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Systemic lupus erythematosus (SLE)<\/td><\/tr><tr><td><strong>Application Type<\/strong><\/td><td>Clinical trial application (China)<\/td><\/tr><tr><td><strong>Submission Date<\/strong><\/td><td>24 Jul 2026<\/td><\/tr><tr><td><strong>Previous Indications<\/strong><\/td><td>IgA nephropathy, myasthenia gravis<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-drug-profile-amp-mechanism-of-action\" class=\"wp-block-heading\">Drug Profile &amp; Mechanism of Action<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Molecular Innovation:<\/strong> <strong>Novel molecular structure<\/strong> with proprietary design enabling simultaneous inhibition of both BAFF and APRIL pathways<\/li>\n\n\n\n<li><strong>Dual-Target Strategy:<\/strong> Unlike single-target BAFF inhibitors (belimumab) or APRIL-focused agents, GenSci136 provides <strong>comprehensive blockade<\/strong> of both cytokines critical for B-cell survival and differentiation<\/li>\n\n\n\n<li><strong>Therapeutic Rationale:<\/strong> Dual inhibition is expected to more effectively suppress <strong>abnormal B cells<\/strong> and <strong>antibody-secreting cells<\/strong>, addressing the root cause of pathogenic autoantibody production in SLE<\/li>\n\n\n\n<li><strong>Development Status:<\/strong> Previously approved for clinical trials in <strong>IgA nephropathy<\/strong> and <strong>myasthenia gravis<\/strong>, demonstrating platform versatility across autoimmune indications<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-scientific-rationale-amp-competitive-differentiation\" class=\"wp-block-heading\">Scientific Rationale &amp; Competitive Differentiation<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Pathway Significance:<\/strong> BAFF and APRIL are key cytokines regulating B-cell maturation, survival, and antibody production\u2014both pathways are implicated in SLE pathogenesis<\/li>\n\n\n\n<li><strong>Enhanced Efficacy Potential:<\/strong> Simultaneous blockade may overcome limitations of single-target approaches, where compensatory upregulation of the non-inhibited pathway can reduce therapeutic effectiveness<\/li>\n\n\n\n<li><strong>Tissue Protection:<\/strong> By more comprehensively suppressing pathogenic autoantibody production, GenSci136 aims to <strong>mitigate tissue and organ damage<\/strong> mediated by humoral immune abnormalities<\/li>\n\n\n\n<li><strong>Class 1 Designation:<\/strong> As a <strong>Chinese Class 1 innovative drug<\/strong>, GenSci136 qualifies for expedited regulatory review and extended market exclusivity upon approval<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-market-opportunity-amp-strategic-implications\" class=\"wp-block-heading\">Market Opportunity &amp; Strategic Implications<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>SLE Treatment Gap:<\/strong> Current SLE therapies include corticosteroids, immunosuppressants, and biologics like belimumab, but significant unmet need remains for more effective and targeted treatments<\/li>\n\n\n\n<li><strong>Addressable Population:<\/strong> China has an estimated <strong>500,000-1 million SLE patients<\/strong>, representing one of the largest SLE populations globally with substantial commercial potential<\/li>\n\n\n\n<li><strong>Platform Validation:<\/strong> Success in SLE would validate GeneScience&#8217;s dual-target platform, potentially enabling expansion into other B-cell mediated autoimmune diseases<\/li>\n\n\n\n<li><strong>Competitive Landscape:<\/strong> Would compete with established biologics (belimumab, anifrolumab) and emerging pipeline candidates, but differentiate through superior target coverage<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-pipeline-context-amp-development-strategy\" class=\"wp-block-heading\">Pipeline Context &amp; Development Strategy<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Multi-Indication Approach:<\/strong> GenSci136&#8217;s development across <strong>SLE, IgA nephropathy, and myasthenia gravis<\/strong> demonstrates strategic portfolio diversification and risk mitigation<\/li>\n\n\n\n<li><strong>Internal R&amp;D Capability:<\/strong> Represents GeneScience&#8217;s ability to develop <strong>globally competitive biologics<\/strong> with novel mechanisms from internal discovery programs<\/li>\n\n\n\n<li><strong>Regulatory Pathway:<\/strong> Clinical trial application submission initiates the formal regulatory review process with China&#8217;s NMPA, with potential first-in-human studies to follow approval<\/li>\n\n\n\n<li><strong>Global Potential:<\/strong> Strong clinical data could support future international development and partnership opportunities beyond the Chinese market<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-investment-considerations\" class=\"wp-block-heading\">Investment Considerations<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Innovation Premium:<\/strong> Class 1 biological products command premium valuations in China&#8217;s biopharmaceutical market due to their novelty and extended protection periods<\/li>\n\n\n\n<li><strong>Subsidiary Value:<\/strong> GeneScience Pharmaceuticals represents a key growth engine within Changchun High-Tech&#8217;s diversified healthcare portfolio<\/li>\n\n\n\n<li><strong>Autoimmune Focus:<\/strong> Strengthens Changchun High-Tech&#8217;s position in the high-value autoimmune disease therapeutic segment<\/li>\n\n\n\n<li><strong>Pipeline Diversification:<\/strong> Adds to the company&#8217;s robust pipeline of innovative biologics across multiple therapeutic areas<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward-looking statements regarding clinical development, regulatory pathways, and market opportunities. Actual results may differ due to clinical trial outcomes, regulatory decisions, and competitive dynamics.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/\u957f\u6625\u9ad8\u65b0\uff1a\u5173\u4e8e\u5b50\u516c\u53f8\u6ce8\u5c04\u7528GenSci136\u5883\u5185\u751f\u4ea7\u836f\u54c1\u6ce8\u518c\u4e34\u5e8a\u8bd5\u9a8c\u7533\u8bf7\u83b7\u5f97\u53d7\u7406\u7684\u516c\u544a.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of \u957f\u6625\u9ad8\u65b0\uff1a\u5173\u4e8e\u5b50\u516c\u53f8\u6ce8\u5c04\u7528GenSci136\u5883\u5185\u751f\u4ea7\u836f\u54c1\u6ce8\u518c\u4e34\u5e8a\u8bd5\u9a8c\u7533\u8bf7\u83b7\u5f97\u53d7\u7406\u7684\u516c\u544a.\"><\/object><a id=\"wp-block-file--media-0d316cf2-9f33-4bad-a0cf-d696a9355ed0\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/\u957f\u6625\u9ad8\u65b0\uff1a\u5173\u4e8e\u5b50\u516c\u53f8\u6ce8\u5c04\u7528GenSci136\u5883\u5185\u751f\u4ea7\u836f\u54c1\u6ce8\u518c\u4e34\u5e8a\u8bd5\u9a8c\u7533\u8bf7\u83b7\u5f97\u53d7\u7406\u7684\u516c\u544a.pdf\">\u957f\u6625\u9ad8\u65b0\uff1a\u5173\u4e8e\u5b50\u516c\u53f8\u6ce8\u5c04\u7528GenSci136\u5883\u5185\u751f\u4ea7\u836f\u54c1\u6ce8\u518c\u4e34\u5e8a\u8bd5\u9a8c\u7533\u8bf7\u83b7\u5f97\u53d7\u7406\u7684\u516c\u544a<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/\u957f\u6625\u9ad8\u65b0\uff1a\u5173\u4e8e\u5b50\u516c\u53f8\u6ce8\u5c04\u7528GenSci136\u5883\u5185\u751f\u4ea7\u836f\u54c1\u6ce8\u518c\u4e34\u5e8a\u8bd5\u9a8c\u7533\u8bf7\u83b7\u5f97\u53d7\u7406\u7684\u516c\u544a.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-0d316cf2-9f33-4bad-a0cf-d696a9355ed0\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Changchun High-Tech Industries (Group) Co., Ltd. (SHE: 000661) announced today that its subsidiary GeneScience Pharmaceuticals&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,11],"tags":[65,2929,90,358,1171],"class_list":["post-70604","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-auto-immune","tag-changchun-high-new-technology-industries","tag-clinical-trial-filings","tag-genescience-pharmaceutical","tag-she-000661"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v28.1) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Changchun High-Tech Subsidiary GeneScience Files SLE Clinical Application for Novel Dual-Target BAFF\/APRIL Inhibitor GenSci136 - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Changchun High-Tech Industries (Group) Co., Ltd. (SHE: 000661) announced today that its subsidiary GeneScience Pharmaceuticals has submitted a clinical trial application in China for GenSci136, a novel Class 1 therapeutic biological product targeting systemic lupus erythematosus (SLE). The investigational agent features a dual-target mechanism simultaneously blocking both BAFF (B-cell activating factor) and APRIL (a proliferation-inducing ligand) signaling pathways, representing a next-generation approach to modulating humoral immunity in autoimmune diseases.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=70604\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Changchun High-Tech Subsidiary GeneScience Files SLE Clinical Application for Novel Dual-Target BAFF\/APRIL Inhibitor GenSci136\" \/>\n<meta property=\"og:description\" content=\"Changchun High-Tech Industries (Group) Co., Ltd. (SHE: 000661) announced today that its subsidiary GeneScience Pharmaceuticals has submitted a clinical trial application in China for GenSci136, a novel Class 1 therapeutic biological product targeting systemic lupus erythematosus (SLE). The investigational agent features a dual-target mechanism simultaneously blocking both BAFF (B-cell activating factor) and APRIL (a proliferation-inducing ligand) signaling pathways, representing a next-generation approach to modulating humoral immunity in autoimmune diseases.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=70604\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-07-24T13:08:57+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-07-24T13:08:58+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70604#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70604\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Changchun High-Tech Subsidiary GeneScience Files SLE Clinical Application for Novel Dual-Target BAFF\\\/APRIL Inhibitor GenSci136\",\"datePublished\":\"2026-07-24T13:08:57+00:00\",\"dateModified\":\"2026-07-24T13:08:58+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70604\"},\"wordCount\":581,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Auto-immune\",\"Changchun High &amp; New Technology Industries\",\"Clinical trial filings\",\"GeneScience Pharmaceutical\",\"SHE: 000661\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=70604#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70604\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=70604\",\"name\":\"Changchun High-Tech Subsidiary GeneScience Files SLE Clinical Application for Novel Dual-Target BAFF\\\/APRIL Inhibitor GenSci136 - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-07-24T13:08:57+00:00\",\"dateModified\":\"2026-07-24T13:08:58+00:00\",\"description\":\"Changchun High-Tech Industries (Group) Co., Ltd. (SHE: 000661) announced today that its subsidiary GeneScience Pharmaceuticals has submitted a clinical trial application in China for GenSci136, a novel Class 1 therapeutic biological product targeting systemic lupus erythematosus (SLE). The investigational agent features a dual-target mechanism simultaneously blocking both BAFF (B-cell activating factor) and APRIL (a proliferation-inducing ligand) signaling pathways, representing a next-generation approach to modulating humoral immunity in autoimmune diseases.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70604#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=70604\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70604#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Changchun High-Tech Subsidiary GeneScience Files SLE Clinical Application for Novel Dual-Target BAFF\\\/APRIL Inhibitor GenSci136\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Changchun High-Tech Subsidiary GeneScience Files SLE Clinical Application for Novel Dual-Target BAFF\/APRIL Inhibitor GenSci136 - Insight, China&#039;s Pharmaceutical Industry","description":"Changchun High-Tech Industries (Group) Co., Ltd. (SHE: 000661) announced today that its subsidiary GeneScience Pharmaceuticals has submitted a clinical trial application in China for GenSci136, a novel Class 1 therapeutic biological product targeting systemic lupus erythematosus (SLE). The investigational agent features a dual-target mechanism simultaneously blocking both BAFF (B-cell activating factor) and APRIL (a proliferation-inducing ligand) signaling pathways, representing a next-generation approach to modulating humoral immunity in autoimmune diseases.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=70604","og_locale":"en_US","og_type":"article","og_title":"Changchun High-Tech Subsidiary GeneScience Files SLE Clinical Application for Novel Dual-Target BAFF\/APRIL Inhibitor GenSci136","og_description":"Changchun High-Tech Industries (Group) Co., Ltd. (SHE: 000661) announced today that its subsidiary GeneScience Pharmaceuticals has submitted a clinical trial application in China for GenSci136, a novel Class 1 therapeutic biological product targeting systemic lupus erythematosus (SLE). The investigational agent features a dual-target mechanism simultaneously blocking both BAFF (B-cell activating factor) and APRIL (a proliferation-inducing ligand) signaling pathways, representing a next-generation approach to modulating humoral immunity in autoimmune diseases.","og_url":"https:\/\/flcube.com\/?p=70604","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-07-24T13:08:57+00:00","article_modified_time":"2026-07-24T13:08:58+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=70604#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=70604"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Changchun High-Tech Subsidiary GeneScience Files SLE Clinical Application for Novel Dual-Target BAFF\/APRIL Inhibitor GenSci136","datePublished":"2026-07-24T13:08:57+00:00","dateModified":"2026-07-24T13:08:58+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=70604"},"wordCount":581,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Auto-immune","Changchun High &amp; New Technology Industries","Clinical trial filings","GeneScience Pharmaceutical","SHE: 000661"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=70604#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=70604","url":"https:\/\/flcube.com\/?p=70604","name":"Changchun High-Tech Subsidiary GeneScience Files SLE Clinical Application for Novel Dual-Target BAFF\/APRIL Inhibitor GenSci136 - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-07-24T13:08:57+00:00","dateModified":"2026-07-24T13:08:58+00:00","description":"Changchun High-Tech Industries (Group) Co., Ltd. (SHE: 000661) announced today that its subsidiary GeneScience Pharmaceuticals has submitted a clinical trial application in China for GenSci136, a novel Class 1 therapeutic biological product targeting systemic lupus erythematosus (SLE). The investigational agent features a dual-target mechanism simultaneously blocking both BAFF (B-cell activating factor) and APRIL (a proliferation-inducing ligand) signaling pathways, representing a next-generation approach to modulating humoral immunity in autoimmune diseases.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=70604#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=70604"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=70604#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Changchun High-Tech Subsidiary GeneScience Files SLE Clinical Application for Novel Dual-Target BAFF\/APRIL Inhibitor GenSci136"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/70604","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=70604"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/70604\/revisions"}],"predecessor-version":[{"id":70606,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/70604\/revisions\/70606"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=70604"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=70604"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=70604"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}